Hawthorne Health
Sponsors & CROs
Partners
Resources
For Patients
About Us
Share your protocol
Home› Resources› The Pulse› Regulation

Regulation · December 2, 2026

GCP now reaches the home: ICH E6(R3) Annex 2

ICH's new annex to good clinical practice covers trial activity away from the investigator's location. It takes effect in the EU on January 15, 2027.

Jun 3, 2026finalized by ICH (Step 4)Draft adopted by the EMA's CHMP November 14, 2024
Jun 25, 2026final adoption by the EMA's CHMPPublished with the consolidated E6(R3) guideline
Jan 15, 2027date for coming into effect in the EUPer the EMA-published text

What the annex covers

Annex 2 adds guidance for decentralised elements, pragmatic trials and the use of real-world data. It defines decentralised elements as trial-related activities conducted outside the investigator's location: visits or procedures at the participant's home, at local healthcare centres or in mobile medical units, and remote interactions such as video calls or the use of digital health technologies.

Three points for 2027 planning

  • Investigational product can be administered at the participant's location by appropriate parties. The annex names site staff, the participant, a home nurse and a local pharmacist as examples.
  • Investigator oversight should be proportionate. The annex ties the level of oversight to how critical the data are to participant protection, from direct supervision to review of essential records.
  • When the sponsor arranges home nursing, the investigator still decides whether the provider is appropriate and oversees their work.

Healthcare professionals may also perform trial-related activities that are part of usual clinical practice. Where an activity needs knowledge of the protocol, trained and delegated staff should perform it.

What it means for sponsors

For sponsors planning hybrid studies, the annex gives home visits and local healthcare settings a defined place inside GCP, with the investigator's oversight kept at the center. The practical work is in the plan: which visits can move, who performs them, and how the investigator sees the records.

Where Hawthorne Health fits

Hawthorne Health has delivered in-home study visits since 2015, in all 50 states, under the same quality system and SOPs as our 9 pharmacy-based community sites. In a below-the-knee cardiovascular program, 96% of study visits were conducted inside the protocol window.

This summary paraphrases the annex. Read the full text before applying it to a protocol.

Sources

  • ICH E6(R3) Guideline for good clinical practice, Annex 2 (Step 4, June 3, 2026), as published by the European Medicines Agency
  • RAPS, ICH adopts GCP Annex 2, June 2026

Related

  • At-home trials
  • Hybrid trials
  • Quality and compliance
  • Case study: 96% of visits in window

Evaluate the network

Send us your protocol.

We will come back with fit, coverage, and an approach for your study.

Share your protocol
All signals

Let’s talk.

Hawthorne Health

Clinical research delivered in the communities where patients live and receive care.

(415) 343-2600info@hawthornehealth.com

Sponsors & CROs
OverviewCase StudiesThe PulseCommunity Site NetworkAt-Home TrialsHybrid TrialsWearable ValidationCapabilitiesTherapeutic ExpertiseInvestigator NetworkRecruitmentCoverage CheckQuality & ComplianceFAQ
Patients
Find a StudyResearch LocationsAbout Clinical ResearchWhat to ExpectYour Rights & SafetyRefer a FriendProvider Referrals
Partners
Become a Site PartnerBecome an InvestigatorLabcorp Collaboration
Company
Hawthorne StoryRecognitionLeadershipCareersNewsroomContact
Copyright © 2026 Hawthorne Health, Inc. | All Rights Reserved
PrivacyTerms